Around fifteen years ago, test kits that analyze the intestinal microbiome—also known as the gut microbiota—became available for purchase by the general public. These kits use a simple stool sample to examine the trillions of microorganisms living in the human gut. Companies selling these tests claimed they could help identify digestive issues, prevent diseases, and offer personalized nutrition and supplement recommendations. The market for these test kits began to grow in the early 2010s and became more organized by 2015, with the United States being one of the first countries to widely adopt the practice, followed by Europe. The emergence of this market is often linked to uBiome, an American startup that launched the first mass-market microbiome analysis kit in 2013 through a crowdfunding campaign. However, uBiome later faced significant legal challenges. The Federal Bureau of Investigation (FBI) investigated the company, leading to the indictment of its executives for medical fraud and overcharging insurance companies. Despite this setback, the market for microbiome test kits continued to grow and expanded globally into the 2020s. Critics of these test kits argue that they lack proper medical oversight and are not yet supported by clear scientific standards. Research has shown that the composition of the gut microbiome varies widely among individuals, even those who are in excellent health. Factors such as geography, diet, and lifestyle can influence these differences. In 2022, a study published in the journal Diabètes by Cedars-Sinai Medical Center in Los Angeles found that microbiome tests marketed to the general public do not provide clinically useful information for doctors or patients. These tests, the study concluded, cannot reliably diagnose diseases or guide medical treatments. As a result, detailed analysis of the gut microbiome is still primarily used in scientific research and laboratory settings. While the idea of personalized health insights based on gut bacteria is appealing, current evidence suggests that these tests are not yet ready to replace traditional medical diagnostics or treatments. Scientists continue to study the microbiome, hoping that future research may lead to more effective applications in healthcare.